Ampicillin Trihydrate

證據等級: L5

預測適應症: 0 個

Ampicillin Trihydrate: Repurposing Evaluation (No TxGNN Prediction Available)

One-Sentence Summary

Ampicillin Trihydrate is a broad-spectrum aminopenicillin antibiotic, widely used to treat bacterial infections including respiratory tract infections, urinary tract infections, and meningitis. The current Evidence Pack contains no TxGNN-predicted new indications for this drug — the prediction pipeline has not yet been run or returned results for this candidate. Without a predicted indication, a formal repurposing evaluation cannot be completed at this time; this report documents current data availability and identifies the gaps that must be resolved before proceeding.

Quick Overview

Item	Content
Original Indication	Bacterial infections (broad-spectrum antibiotic: respiratory, urinary tract, CNS, GI)
Predicted New Indication	Not available — no TxGNN prediction returned
TxGNN Prediction Score	N/A
Evidence Level	N/A (prediction pipeline not executed)
Malaysia Market Status	✓ Marketed
Number of Registrations	9
Recommended Decision	Hold — critical data gaps must be resolved first

Drug Background

Ampicillin Trihydrate is the stable trihydrate salt form of ampicillin, a broad-spectrum beta-lactam antibiotic of the aminopenicillin subclass. It has been in clinical use since the 1960s and remains on the WHO Essential Medicines List.

Mechanism of Action (from general knowledge — DrugBank query pending): Ampicillin exerts bactericidal activity by irreversibly binding to penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls. This inhibits the transpeptidase enzyme responsible for peptidoglycan cross-linking, thereby disrupting cell wall synthesis and ultimately causing bacterial cell lysis. Its aminobenzyl side chain provides extended gram-negative coverage compared to earlier penicillins.

⚠️ Data Gap DG002 (High): Formal MOA data has not been retrieved from DrugBank for this Evidence Pack. The description above is based on established pharmacological knowledge and should be verified against the DrugBank API record before formal reporting.

Established Indications: Ampicillin is approved for infections caused by susceptible organisms, including:

Upper and lower respiratory tract infections (Haemophilus influenzae, Streptococcus pneumoniae)
Urinary tract infections (E. coli, Enterococcus faecalis)
Gastrointestinal infections (Salmonella, Shigella)
Bacterial meningitis, endocarditis, and septicemia

TxGNN Prediction Status

The predicted_indications field in the Evidence Pack is empty. This means one of the following scenarios has occurred:

Possible Cause	Recommended Action
Prediction pipeline was not executed for this drug	Run `scripts/run_kg_prediction.py` with Ampicillin Trihydrate as input
DrugBank ID mapping failed (DrugBank ID is `null`)	Resolve DrugBank ID mapping; canonical ID is DB00415 (ampicillin)
Drug name normalisation mismatch	Check if “AMPICILLIN TRIHYDRATE” normalises correctly to the KG node
No significant repurposing signal above threshold	Review prediction threshold settings

Until a TxGNN prediction is available, the core sections of this report (clinical trial evidence, literature evidence, mechanism rationale) cannot be populated.

Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing target — no predicted indication available.

Literature Evidence

Currently no related literature available — no predicted indication to search against.

Malaysia Market Information

The Evidence Pack confirms 9 active registrations in Malaysia; however, all individual licence detail fields (licence number, product name, dosage form, manufacturer, approved indication) were returned as empty strings in the current data pull.

⚠️ Detailed licence records must be retrieved from the NPRA portal before this section can be completed.

Authorization Number	Product Name	Dosage Form	Approved Indication
(9 licences confirmed)	Details not available in current data pack	—	—

Recommended action: Re-query NPRA with the MAL licence number range or retrieve the full registration detail via the NPRA product search API to populate this table.

Safety Considerations

⚠️ Data Gap DG001 (Blocking): TFDA/NPRA package insert warnings and contraindications have not been retrieved. This gap is classified as Blocking and prevents completion of the S1 safety pre-screening stage.

Please refer to the approved package insert for full safety information. Key areas to retrieve include:

Hypersensitivity / anaphylaxis warnings (cross-reactivity with cephalosporins)
Contraindications in penicillin-allergic patients
Renal dose adjustment requirements
Drug interactions (anticoagulants, oral contraceptives, allopurinol, bacteriostatic antibiotics)

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline has not returned any repurposing candidates for Ampicillin Trihydrate, and two critical data gaps (package insert safety data and DrugBank MOA) remain unresolved. A formal repurposing evaluation cannot be conducted without a predicted indication target.

To proceed, the following is needed:

Resolve DrugBank ID mapping — Confirm the canonical DrugBank ID (DB00415 for ampicillin) and re-run the KG prediction pipeline to generate predicted_indications.
Retrieve package insert data (DG001 — Blocking) — Download the NPRA/TFDA package insert PDF and parse warnings, contraindications, and drug interaction data.
Retrieve MOA from DrugBank (DG002 — High) — Query the DrugBank API to obtain structured pharmacology and mechanism data.
Populate NPRA licence details — Re-query NPRA to retrieve full licence records (product names, dosage forms, approved indications) for all 9 registrations.
Re-run evidence collection — Once a predicted indication is available, execute the ClinicalTrials.gov and PubMed collectors to populate the evidence tables.
Re-issue this report — After the above steps, re-generate the Evidence Pack (target version v5) and produce a complete evaluation report.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.